{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:47Z","timestamp":1792093787792,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.diabres.2013.12.011","type":"journal-article","created":{"date-parts":[[2013,12,25]],"date-time":"2013-12-25T15:45:40Z","timestamp":1387986340000},"page":"458-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study"],"prefix":"10.1016","volume":"103","author":[{"given":"Astrid","family":"Breitschaft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Hermosillo Res\u00e9ndiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Golor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2013.12.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2013.12.011_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diabetes.48.1.77","article-title":"Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis","volume":"48","author":"Kumar","year":"1999","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.diabres.2013.12.011_bib0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/0091270011408727","article-title":"Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers","volume":"52","author":"Petersenn","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2013.12.011_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/JOE-11-0224","article-title":"Effects of somatostatin analogues on glucose homeostasis in rats","volume":"212","author":"Schmid","year":"2012","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2013.12.011_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.diabres.2013.12.011_bib0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month Phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2013.12.011_bib0035","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.diabres.2013.12.011_bib0040","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.diabres.2013.12.011_bib0045","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2013.12.011_bib0050","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"issue":"9662","key":"10.1016\/j.diabres.2013.12.011_bib0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2013.12.011_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000314319","article-title":"Pathophysiology of diabetes mellitus in Cushing's syndrome","volume":"92","author":"Pivonello","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"11","key":"10.1016\/j.diabres.2013.12.011_bib0065","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1210\/jc.2001-011766","article-title":"Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk","volume":"87","author":"Tauchmanova","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9522","key":"10.1016\/j.diabres.2013.12.011_bib0070","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing's syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.diabres.2013.12.011_bib0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","article-title":"The burden of Cushing's disease: clinical and health-related quality of life aspects","volume":"167","author":"Feelders","year":"2012","journal-title":"Eur J Endocrinol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822713004440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822713004440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T16:55:33Z","timestamp":1538931333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822713004440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0168822713004440"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2013.12.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718255105.793511710","asserted-by":"object"}]},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2013.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}